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Abstract: It is estimated that by 2023, approximately 20% of the population of Western Europe and
North America will suffer from a degenerative joint disease commonly known as osteoarthritis
(OA). During the development of OA, pro-inflammatory cytokines are one of the major causes that
drive the production of inflammatory mediators and thus of matrix-degrading enzymes. OA is a
challenging disease for doctors due to the limitation of the joint cartilage’s capacity to repair itself.
Though new treatment approaches, in particular with mesenchymal stem cells (MSCs) that integrate
the tissue engineering (TE) of cartilage tissue, are promising, they are not only expensive but more
often do not lead to the regeneration of joint cartilage. Therefore, there is an increasing need for
novel, safe, and more effective alternatives to promote cartilage joint regeneration and TE. Indeed,
naturally occurring phytochemical compounds (herbal remedies) have a great anti-inflammatory,
anti-oxidant, and anabolic potential, and they have received much attention for the development
of new therapeutic strategies for the treatment of inflammatory diseases, including the prevention
of age-related OA and cartilage TE. This paper summarizes recent research on herbal remedies and
their chondroinductive and chondroprotective effects on cartilage and progenitor cells, and it also
emphasizes the possibilities that exist in this research area, especially with regard to the nutritional
support of cartilage regeneration and TE, which may not benefit from non-steroidal anti-inflammatory
drugs (NSAIDs).
Keywords: herbal remedies; cartilage; tissue engineering; osteoarthritis; curcumin; icariin;
pomegranate; ginger; avocado/soybean unsaponifiables; resveratrol
1. Introduction
Currently, about 200 joint diseases are characterized by the term “osteoarthritis” (OA), also known
as degenerative joint disease (DJD). OA is reported as the main cause of pain and disability in the
joints of older people [1], and the joints most commonly affected by OA are the hip, knee, hand,
and spine [2,3]. In addition, it has been reported that 20 percent of adults in Western Europe and
North America will be exposed to OA by 2030 [4], and OA can be expected to be a significant economic
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burden on health systems and medical facilities worldwide [5]. OA is predominantly defined and
characterized by the microtrauma and degradation of articular cartilage [6], massive intra-articular
inflammation with synovitis, arthritis, and changes in periarticular structures and subchondral bone
tissue [7]. Though OA affects all structures of the synovial joint [8], the degeneration and degradation
of articular cartilage is the main cause of clinical symptoms, making cartilage regeneration the focus of
attention and the basis for long-term treatment success [9–11]. Up to now, the treatment of OA has
concentrated on anti-inflammatory therapies (mainly non-steroidal anti-inflammatory drugs (NSAIDs)
to relieve pain) and preventive measures to improve the lifestyle of the patient (weight control, exercise,
and nutritional advice) [12,13]. However, common clinical treatments with chemical agents and
synthetic drugs do not have a cartilage-regenerating effect and are associated with several undesirable
side effects. Therefore, there is a significant need for alternative, better regenerative approaches for the
success in the long-term treatment of OA [14].
The cartilage tissue belongs to the family of bradytrophic connective tissues. Due to its unique
macro- and microstructural composition and its highly organized structure, cartilage tissue poses a
great challenge for researchers who want to repair and regenerate this highly specific tissue [15,16].
The unique architecture of articular cartilage consists of chondrocytes that produce and are embedded
in a cartilage-specific, highly organized extracellular matrix (ECM). The main component of this ECM
is water (60–80%), which is closely bound to the macromolecular components that consist of 40–50%
collagens (90% collagen type II: COL2A1) and 20–25% of various specialized proteoglycans (aggrecan,
decorin, biglycan, and fibromodulin) [17]. The cartilage-specific ECM is not only synthesized by the
chondrocytes, as they are also in close functional interaction with each other and their production
in the chondrocytes is stimulated and directly influenced by highly sensitive microenvironmental
conditions that stimulate cartilage homeostasis and repair [18].
The main problem is that although cartilage tissue has a basic regenerative potential, it actually
contains additional progenitor cells, mesenchymal stem cells (MSCs), which are the basic prerequisite
for adequate tissue regenration, since under pathological conditions only repair tissue develops [19–21].
However, the repair tissue is not capable of withstanding physiological stress on the cartilage tissue in
the joints, resulting in joint degeneration, the impairment of joint use, dysfunction, deformation, pain,
and a considerable impairment of the patient’s everyday life [15,16].
In fact, for appropriate chondrogenesis, MSCs require an adequate stimulus through the external
application of growth factors and cytokines, such as transforming growth factor-β (TGF-β), insulin-like
growth factor−1 (IGF−1), and bone morphogenic protein−6 (BMP−6) [22–26].
The term “tissue engineering” (TE) is defined as the ability to reconstruct mammalian tissue
both in structure and function [27]. In fact, the broad and extensive field of TE has emerged as a
promising new branch of modern medicine aimed at realizing mankind’s dream of developing the
ability to reconstruct functional transplantable tissues [28,29]. In recent decades, modern medicine
has greatly enhanced our capabilities and reached many milestones in improving TE approaches,
including cartilage TE [30,31]. However, common treatment approaches such as endoprosthetics,
multiple drilling, microfractures, autologous chondrocyte implantation (ACI), and joint replacement
are associated with many side effects [32,33]. In addition, there are still many limitations in creating
an adequate cellular microenvironment: The scaffolds used must be biocompatible, biodegradable,
non-toxic, and have the desired mechanical properties, and the materials used can be expensive and
have not yet been fully tested [25].
In the attempt to refine and improve TE approaches for cartilage tissue and to find new, better,
safer, and cheaper alternatives, attention has been drawn to natural, non-toxic, and anabolic active
components from nature [34–37]. In traditional medicine, such as Ayurveda medicine (the science of
long life) or traditional Chinese and Indian medicine, herbal remedies have been used for centuries
to treat many diseases, including joint diseases. More recently, the use of herbal remedies and their
derivatives to treat joint problems, including OA, has also become widely accepted in modern Western
medicine due to their proven anabolic, anti-inflammatory, health, and medical benefits [38–42]. Indeed,
Molecules 2020, 25, 3075 3 of 25
there are a wealth of studies on the efficacy of herbal ingredients and their use in the treatment of
a number of diseases, including anti-inflammatory effects on chondrocytes [14,35,43–45]. A major
advantage of using herbal remedies for prevention and therapeutic treatment is also that they are
accessible to a broad range of people at relatively low cost, are safe to use, and have no undesirable
side effects. Though a proper scientific assessment of herbal medicinal products is a challenge, many
practices in modern delivery systems have investigated the use of herbal medicines in biotechnology
to overcome rheumatoid arthritis (RA) and OA. Here, herbal medicinal products are studied as
raw herbs, herbal mixtures, herbal fusions, finished herbal products, or over-the-counter drugs [46].
Various processes such as steaming, roasting, or cooking could improve the properties and their effects.
The preparation and the method of application and administration of herbs is crucial for the final results.
The basis for herbal preparations is powdered herbal materials or extracts, tinctures, and fatty oils from
herbal materials produced by extraction, fractionation, purification, concentration, or other physical or
biological processes. Indeed, the study of the appropriate use of herbal medicine and herbal chemicals
in TE should be considered as a suitable and substantial approach to the repair and regeneration of
articular cartilage [46]. Therefore, this literature review focuses on the potential of herbal remedies
as anti-oxidant and anti-inflammatory agents and their potential for cartilage regeneration and TE
therapy, as well as the prevention and treatment of joint diseases, with a focus on OA.
Data Acquisition
The search was limited to scientific publications, journals, and textbooks. Both in vivo and in vitro
studies were equally evaluated. The included data, abstracts, titles, and full texts were reviewed by
two independent researchers to determine the relevance for inclusion in the study. The search terms
used were ‘cartilage,’ ‘degenerative joint diseases,’ ‘tissue engineering,’ ‘herbal medicinal products,’
‘nutraceuticals,’ ‘herbal remedies,’ and ‘osteoarthritis.’ Herbal remedy-related search terms were
‘icariin,’ ‘pomegranate,’ ‘ginger,’ ‘avocado/soybean unsaponifiable (ASU),’ ‘curcumin,’ and ‘resveratrol,’
as well as the term ‘herb’ and all its derivatives, combining the words with individual plant and herb
names (Figure 1). No methodological search filter was applied. Scientists working in similar fields of
study were contacted to evaluate the results and conclusions of the related literature. In case additional
information was needed, the authors were contacted whenever possible.
Tables 1–6 give a short overview of the reviewed studies. The accuracy of the data was validated
by all authors.
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Figure 1. Structures of natural products with potential for cartilage regeneration, tissue engineering
(TE), and the prevention and treatment of joint diseases.
2. Curcumin
Natural polyphenol curcumin (diferuloylmethane) is the main active ingredient in turmeric
(Curcuma Longa, also called curry) and derived from its rhizomes. Due to its anti-inflammatory and
anti-oxidant properties, curcumin has a wide-range of medicinal applications including targeting
cancers, diabetes, obesity, cardiovascular, pulmonary, neurological, and autoimmune diseases [47].
In fact, curcumin is used in traditional Indian Ayurvedic medicine to treat diarrhea, abdominal pain,
nausea, intestinal gases, loss of appetite, jaundice, liver problems, gall bladder issues, and OA [43].
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In OA treatment, curcumin has been recognized to target the catabolic-induced inflammatory
effects of interleukin−1 beta (IL-1β) signaling, such as the matrix metalloproteinase−13 (MMP−13)
up-regulation and inhibition of matrix synthesis, by exhibiting a chondroprotective effect [36].
Additionally, curcumin inhibited IL-1β- or tumor necrosis factor (TNF)-α- or TNF-β-induced inhibition
of COL2A1, cartilage-specific proteoglycans (CSPGs), and β1-integrin synthesis in chondrocytes and
blocked IL-1β-, TNF-α-, or TNF-β-induced apoptosis by caspase−3 inhibition [37,48,49]. Furthermore,
curcumin was shown to suppress pro-inflammatory signaling pathways in human and rat articular
chondrocytes by targeting IL-1β-induced transcription factor nuclear factor kappa B (NF-κB) activation
and the suppression of NF-κB-regulated gene end-products such as cyclooxygenase−2 (COX−2) and
MMP−9 [37,50]. Moreover, in IL-1β-stimulated cartilage explants, curcumin was able to block the
IL−1β-induced loss of glycosaminoglycans (GAGs) [51]. Contrary to these findings, a comparative study
investigating the effect of glucosamine (GlcN), curcumin, and diacerein in human chondrocytes found
that curcumin was not as effective as GlcN and diacerein in stimulating expression of cartilage-specific
genes such as aggrecan (AGC) and COL2A1, and it was even toxic at high concentrations [52].
Interestingly, a study by Buhrmann and co-workers (2010) showed a significant protective and
stimulating effect of curcumin on the chondrogenesis of MSCs [53]. Here, a four-hour pre-treatment
with curcumin significantly increased the production of COL2A1, CSPGs, and β1-integrin, as well as
the activation of the mitogen-activated protein (MAP) kinase signaling pathway and the suppression
of caspase−3 and COX−2. Moreover, in IL-1β-stimulated three dimensional co-cultures of MSCs and
primary chondrocytes, curcumin inhibited the inflammatory effect of IL-1β and thereby stimulated
adequate chondrogenesis [53]. These results underline the enormous potential of curcumin to suppress
inflammatory signaling pathways and thereby create an appropriate anabolic and stimulatory
microenvironment for chondrogenesis.
Several studies have shown and evaluated curcumin-loaded electrospinning PLA (poly(lactic
acid)) composite membranes and could demonstrate that curcumin dose-dependently decreased the
average diameters of composite nanofibers, resulting in the superior anti-coagulation property of
composite membranes compared to pure PLA membranes [54,55]. These strategies can support the
specific potential regeneration of joint cartilage tissue [53,54]. Furthermore, Henrotin et al. (2010)
summarized the protective effects of curcumin on articular chondrocytes, and they reported that
curcumin protects chondrocytes from catabolic effects of IL-1β including MMP−3 up-regulation, the
inhibition of COL2A1, and the down-regulation of β1-integrin expression. Indeed, curcumin blocks
IL-1β-induced PG degradation, activator protein-1 (AP-1)/NF-κB signaling pathways, chondrocyte
apoptosis, and the activation of pro-apoptotic proteins, such as caspase−3 [43]. Interestingly, a study
by Golchin and co-workers (2019) showed that nanofibrous scaffolds fabricated by chitosan, poly(vinyl
alcohol) (PVA), carbopol, and polycaprolactone using a dual electrospinning technique that had
curcumin incorporated inside the chitosan (CS)/PVA fibers exerted better bactericidal activity against
Gram-positive bacterial strains compared to Gram-negative strains and demonstrated significant
compatibility with blood and fibroblast cells, making this curcumin scaffold combination a promising
candidate for TE [56]. In addition, in a scaffold of curcumin and silk fibroin the GAG content and
the analysis of mRNA expression indicated that the chondrocytes remained viable and continued to
proliferate. Furthermore, the composition of the curcumin-silk scaffold showed a high biocompatibility
and a favorable microenvironment for cartilage repair after transplantation in vivo [57]. In fact, several
studies have shown that curcumin modulates the effects of pro-inflammatory cytokines such as the
IL-1β-, or TNF-α, or TNF-β-induced suppression of specific cartilage ECM and signal molecules, such
as integrins in human joint chondrocytes by antagonizing the IL-1β-, TNF-β-, or TNF-α-dependent
up-regulation of pro-inflammatory biomarkers, such as MMP−9, caspase−3, and COX−2. More
interestingly, curcumin blocks cytokines that promote the phosphorylation and nuclear translocation
of the pro-inflammatory transcription factor subunit p65-NF-κB by the phosphorylation, degradation,
and ubiquitination of IκB-α [37,48,49,57,58]. Taken together, these data suggest that curcumin has
cartilage regeneration capacity as a naturally occurring anti-inflammatory multi-targeted compound
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for the treatment of OA or RA through the suppression of the master pro-inflammatory transcription
factor NF-κB signaling pathways in chondrocytes.
Table 1. Curcumin application in cartilage tissue engineering.
First Author References Experimental Model Study Type Findings
Shakibaei [37]
The effects of curcumin were
investigated in primary human
chondrocytes (PCH) treated with
interleukin-1 beta (IL-1β), tumor
necrosis factor alpha (TNF-α). 90%
collagen type II (COL2A1), integrin
β1, cyclooxygenase-2 (COX-2), matrix
metalloproteinase 9 (MMP-9), and the
phosphorylation and nuclear
translocation of NF-kB were analyzed.
in vitro/human
chondrocytes
Curcumin as a naturally occurring
anti-inflammatory agent for the
treatment of osteoarthritis (OA) by





PCH from human samples treated
with diverse cytokines, such as




TNF-β is involved in the
inflammatory microenvironment
in PCH, similar to TNF-α, which
leads to an upregulation of NF-κB
signaling. The curcumin-inhibited




PCH were pretreated with IL-1β, in
monolayer and 3D-cultures with
curcumin. The ultrastructure of PCH
was investigated by TEM. The
production of COL2A1, the β1








has potential as an adjunct
nutraceutical chondroprotective
agent for treating OA and related
osteoarticular disorders.
Wang [50]
Chondrocytes were treated with IL-1β










agent for the treatment of OA by
inhibition of NF-κB signaling.
Buhrmann [53]
Mesenchymal stem cells (MSCs) were
cultured in a ratio of 1:1 with primary
chondrocytes in 3D-high-density





microenvironment, in which the





nanofibers of a blend of PLA and
HPG for wound healing applications.







nanofibers can be a potential
wound patch dressing for acute
and chronic wound applications.
Golchin [56]
Nanofibrous scaffolds fabricated by
chitosan (CS), PVA, carbopol, and
polycaprolactone using a dual
electrospinning technique while






This nanofibrous scaffold has
great potential, as simultaneous
administration of curcumin and
BFP-MSCs holds the promising




Scaffold composed of curcumin and
silk fibroin as an appropriate clinical
replacement for defected cartilage.
The scaffolds were designed to have
adequate pore size and mechanical
strength for cartilage repair.
in vitro/in vivo rat
chondrocytes
The curcumin/silk scaffold
showed its biocompatibility, a
favorable environment for
post-transplant cartilage repair
in vivo. A functional composite
scaffold of curcumin/silk can be
used in cartilage-tissue




Ginger (Zingiber officinale) has been an important ingredient in Asian herbal medicine for centuries
and is used especially for pain relief in diseases of the musculoskeletal system [59]. Moreover, ginger
consists of a complex combination of biologically active ingredients, of which the compounds gingerols,
shogaols, and parasols appear to account for the majority of its anti-inflammatory properties [60].
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In addition, gingerol suppresses inflammatory degradation enzymes such as the nitric oxide (NO)
synthase or COX-2, which have been shown to be regulated and promoted by the master transcription
factor NF-κB [60]. In fact, the composition of ginger extraction varies according to the type of ginger,
the maturity of the rhizome, the climate in which the plants are grown and harvested, and the
process of extract preparation [61,62]. A meta-analysis of randomized controlled trials comparing
oral ginger treatment with placebo in OA patients showed that ginger extracts had a variable and
usually modest effect with a reduction in pain and a reduction in the disability of OA symptoms,
and the extracts were well tolerated by the majority of patients [61]. Furthermore, in vitro analyses
have shown that ginger can act as an inhibitor of COX, in particular of the inducible form of
COX-2 rather than the constitutive form COX-1 [63]. In addition, ginger suppresses arachidonate
5-lipoxygenase, an enzyme of leukotriene biosynthesis, resulting in the suppression of the synthesis
of inflammatory leukotrienes [64]. Indeed, in vitro studies have revealed that ginger also exerts
its anti-inflammatory protective effects on chondrocytes and human synoviocytes by specifically
decreasing the production of inflammatory mediators and chemokines induced by lipopolysaccharides
(LPS), IL-1β, and/or TNF-α [65,66]. Furthermore, it has been shown that ginger root extract (GRE)
significantly suppresses the production of NO and prostaglandin E2 (PGE2) in cartilage tissue grafts
in vitro, and it linearly reduces production of PGE2 and NO in both normal and OA chondrocytes [66,67].
In addition, ginger extract efficiently suppressed the expression of pro-inflammatory cytokines, such
as TNF-α, interleukin-6, and interleukin-8 mRNA levels, and it significantly reduced levels of both
p38-mitogen-activated protein kinase (MAPK) and c-Jun n-terminal kinase phosphorylation, thereby
reducing cartilage inflammations and degradation [68].
In a study by Hosseinzadeh and co-workers (2017), the toxicity of ginger on chondrocytes
was investigated, and no cytotoxicity was observed even at high concentrations of ginger extract
in chondrocyte cells [69]. In addition, they reported that ginger extract could significantly reduce
IL-1β-induced oxidative stress, mitochondrial changes, and apoptosis [69]. Taken together, these data
support the argument that ginger has positive prevention and pharmaceutical effects against OA
and substantiates the enormous potential and promising role of ginger in stimulating an adequate
chondrogenic microenvironment by suppressing inflammation due to arthritis, thus stimulating
cartilage regeneration and TE.
Table 2. Ginger application in cartilage tissue engineering.
First Author References Experimental Model Study Type Findings
Bartels [61]
Meta-analysis evaluating
the clinical efficacy and





Ginger lead to a statistically
significant reduction in pain and
OA symptoms compared to
placebo control group and was













nitric oxide (NO) and
prostaglandin E2 (PGE2) were
significantly reduced with
ginger extract in chondrocytes
and cartilage explants.
Ruangsuriya [68]
Zingerone was prepared in
dimethyl sulphoxide
(DMSO) and diluted to




expression of TNF-α, IL-6, and
IL-8 mRNA levels and reduced
p38-mitogen-activated protein
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4. Icariin
Icariin, commonly known as horny goat weed or Yin Yang Huo, is a bioactive flavonoid and
phytoestrogen compound extracted from Epimedium that has been widely used in Asian countries
practicing Chinese Traditional Medicine to treat conditions from hay fever and fatigue to atherosclerosis
and osteoporosis [70].
Several reports have shown that icariin has great anti-inflammatory potential, and it has been
investigated in a variety of diseases, including cancer and OA, by modulating autophagy and apoptosis;
it ultimately been indicated to be a promising compound for cartilage TE in the treatment of OA [71,72].
In fact, in vitro studies with icariin have shown that it plays a protective role in OA by promoting
chondrocyte differentiation, reducing chondrocyte apoptosis, and enhancing the secretion of specific
ECM components by chondrocytes [73,74]. In addition, studies on chondrocytes of newborn mice
showed that icariin pretreatment had protective effects against LPS-induced MMP, COX-2, and
inducible nitric oxide synthase (iNOS) expression and reduced ECM production [75]. Interestingly,
a study has demonstrated that higher concentrations of icariin (1 × 10−5 M) may have a better
chondroprotective effect, leading to increased ECM production [74]. Here, the promotion of icariin
in the synthesis of GAGs and collagen in chondrocytes could be due to its ability to upregulate the
expression of the AGC, COL2A1, and SOX9 genes and to additionally downregulate the expression
of the collagen type I gene in chondrocytes. Furthermore, icariin has been shown to be a safe and
effective chondrocyte anabolic agent that stimulates chondrocyte proliferation and attenuates the
breakdown of the ECM [75,76] by the activation of the miR-206 targeting of cathepsin K in rats,
making it a promising candidate for supporting chondrogenesis in TE [77]. Moreover, in a study
with MSCs from bone marrow, icariin effectively supported chondrogenesis by upregulating the
mRNA expression levels and protein synthesis of COL2A1, AGC, and SOX9, as well as suppressing
hypertrophic cartilage markers [78]. Several studies have investigated the potential of icariin in
combination with biocompatible scaffolds as a basis for cartilage TE. Kankala and co-workers (2018)
demonstrated the excellent adhesion rate and growth behavior of chondrocytes in in vitro cartilage
cell proliferation experiments with a highly porous 3D scaffold based on cell-responsive polymeric
inks, i.e., sodium alginate and gelatin (SA-Gel, 1:3 ratio), by a novel 3D printing method, and they
found the porous architectures facilitated the efficient distribution of chondrocytes with only a few
remaining on the surface. Interestingly, they found that icariin addition at a concentration of 10 µg/mL
significantly enhanced the proliferation and viability of chondrocytes, indicating that icariin may
have potential in engineering complex cartilage tissue constructs toward applications in cartilage
TE [79]. In another study, icariin in combination with a hyaluronic acid–icariin hydrogel compound
showed controlled drug release and good cytocompatibility, suggesting this combination as a potential
scaffold for cartilage TE [80]. In addition, a study by Liu and co-workers in 2018 investigated the
release behavior of icariin from gelatin/hyaluronic acid (gel/HA) microspheres and found that icariin
had chondroprotective potential in a rat model of dexamethasone-induced cartilage lesion by the
stimulation of miR-206, which acts on cathepsin K [77]. Interestingly, it has been further shown that
chondrocytes encapsulated in icariin–HA/Col hydrogel showed a tendency to aggregate into larger
clusters. The expression level of chondrogenic genes was remarkably upregulated, and the matrix
synthesis of sGAG and type II collagen was significantly increased. Furthermore, the in vivo study
showed that icariin–HA/Col constructs facilitated the reconstruction of the osteochondral interface in
subchondral defects in rabbits. In the icariin–HA/Col group, the neocartilage layer contained more
type II collagen, and the newly formed subchondral bone deposited abundant type I collagen. Taken
together, these data suggest that the icariin–HA/Col hydrogel may be a promising scaffold for the
reconstruction of an osteochondral interface, thereby promoting the restoration of the osteochondral
defect and for TE [77,80,81]. Furthermore, in a chondrocyte alginate hydrogel 3D culture, icariin was
able to increase proliferation, enhance chondrogenic marker expression, promote ECM synthesis, and
markedly suppress catabolic gene expression including MMP-2, MMP-9, MMP-13, Adamts4, and
Adamts5, possibly due to its role in activating HIF-1α [82]. Moreover, after transplantation into a
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mouse model, the icariin-loaded 3D hydrogel culture of chondrocyte alginate hydrogel significantly
improved osteochondral defects and increased articular chondrocyte repair, as shown by higher
histological scores [82]; additionally, in an in vitro study with a highly porous 3D scaffold based
on sodium alginate and gelatin in 3D printing, icariin significantly promoted the proliferation of
chondrocytes [79]. Additionally, in an in vivo study on the anterior cruciate ligament of the mouse in
which a model of OA and a micro mass culture of mouse chondrocytes were induced, treatment with
icariin resulted in an increased cartilage thickness; an upregulated expression of COL2A1; a reduced
chondrocyte hypertrophy; a downregulated expression of collagen type X and MMP13; an upregulated
expression of AGC, SOX9, and parathyroid hormone related proteins (PHrP); and a down-regulation
of Indian hedgehog (Ihh) and genes regulated by Ihh [83–85].
Taken together, the results of these different in vitro and in vivo studies clearly indicate that the
integration of icariin into different scaffolds and direct administration into the joint could be a very
promising approach to improve cartilage regeneration and TE.
Table 3. Icariin application in cartilage tissue engineering.
First Author References Experimental Model Study Type Findings
Zhang [72]
Natural extracellular matrix (ECM)/PLLA
scaffolds loading Ica (icariin),
Ica–2-hydroxypropyl-β-cyclodextrin
were prepared via phase separation,
solvent replacement and freeze drying.
in vitro/chondrocytes
Ica–2-hydroxypropyl-β-cyclodextrin
inclusion complex-loaded PLLA scaffolds are
suitable for cartilage TE.
Wang [73] Ica was added to the chondrogenicmedium in bone marrow MSCs cultures.
in vitro/chondrocytes,
MSCs
Ica is an accelerant of growth factors for
cartilage TE by promoting chondrogenesis of
bone marrow MSCs but not hypertrophy.
Zhang [74]
Rabbit chondrocytes were isolated and




Ica is an effective accelerant for
chondrogenesis by up-regulation of the
expression of aggrecan (AGC), COL2A1, and
SOX9 genes. Ica-loaded biomaterials have
the potential for cartilage TE.
Liu [75]
Murine chondrocytes were treated with
lipopolysaccharides (LPS) and




Ica is a safe anabolic agent of chondrocytes,
inhibits NO and MMP synthesis and may
exert its protective effects by inhibition of NO
and MMP synthesis, reduces the ECM
destruction.
Kankala [79]
Fabricated porous sodium alginate and
gelatin 3D scaffold by 3D printing
method. Cells were incubated with Ica.
in vitro/chondrocytes
Ica significantly enhanced the proliferation of
chondrocytes, suggesting application for
cartilage TE.
Yang, Li [80,81]
Ica conjugated hyaluronic acid/collagen
hydrogel were used for osteochondral
defect repair.
in vitro/chondrocytes
Ica–hyaluronic acid (HA)/Col constructs
facilitated reconstruction of osteochondral
interface in rabbit subchondral defects.
Ica–HA/Col hydrogel is a promising scaffold
for restoring of osteochondral defect,
suggesting application for cartilage TE.
Wang [82] Cells were seeded in plates, maintained innormal medium with Ica.
in vitro/in vivo
chondrocytes
Ica treatment upregulated mRNA levels of
SOX9, COL2A1, and AGC in the 3D cultures.
Ica significantly enhanced cartilage repair.
Luo [83]
Ica was administered into the
chondrogenic medium for micromass
culture of mouse chondrocytes.
in vitro/in vivo
mouse chondrocytes
In mouse model of OA and chondrocytes in
micromass cultures, Ica treatment reduced
destruction of cartilage, promoted
chondrocyte differentiation, upregulated
expression of parathyroid hormone related
proteins (PHrP), down-regulated the
expression of Indian hedgehog (Ihh).
Liu, Zhang [84,85]
Injectable thiolated Ica functionalized
Col/HA hydrogel to promote cartilage
formation. Ica-conditioned serum
engineered with hyaluronic acid, articular
cartilage defects in rabbit knees.
in vitro/in vivo
cartilage
Ica–Col/HA hydrogel had great potential for
clinical application in articular cartilage
repair. Ica-conditioned serum combined with
HA promotes reparative response in cartilage




Avocado and soybean extract, known as avocado/soybean unsaponifiables (ASUs), is a natural
remedy derived from avocado and soybeans [86]. It is a plant-based extract that consists of one third
avocado oil and two thirds soybean oil [87]. Though its mechanism of action is not yet fully understood,
it exerts an anti-inflammatory potential that prevents the degeneration of cartilage and joints and
supports the regeneration of connective tissue [46]. Overall, it has been shown that ASU components
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exert anti-inflammatory and pro-anabolic effects in chondrocytes and enhance chondroprotective
properties by stimulating the production of type II collagen and CSPGs [22,23]. It has been reported
that ASUs’ most widely used commercial product for the treatment of OA is Piascledin, which
contains extracts of avocado and soybeans in a 1:2 ratio [88,89]. Several in vitro studies have shown
that Piascledin has an inhibitory effect on type II collagenase and prostaglandins, stimulates the
synthesis of PGs and COL2A1, and reduces the synthesis of fibronectin, thereby improving cartilage
formation [24,90]. Moreover, it has been shown that IGFBP-3-fibronectin interactions affect the IGF-I
pathway, and it has been indicated that IGF-I is deposited in the chondrocyte matrix by binding to
a complex of IGFBP-3 and intact fibronectin. This setup could play an important role in the control
mechanisms of cartilage damage [24]. Additionally, Piascledin inhibits the effect of pro-inflammatory
cytokines such as IL-1β and has a stimulatory effect on the synthesis of COL2A1 in chondrocytes and
on TGF-β1 [91].
Furthermore, it has been shown that ASU can stimulate the expression of TGF-β1 and TGF-β2
in chondrocytes in vitro, and in vivo studies have shown that ASU increases levels of TGF-β1 and
TGF-β2 in knee synovial fluid, thereby significantly reducing OA lesions. Interestingly, in an in vivo
study, it was shown that ASU treatment showed significant symptomatic efficacy versus placebo in the
treatment of OA, which occurred from the second month and even showed a sustained effect after the
end of treatment [92–94]. Furthermore, ASU potently inhibits the production of IL-8 and PGE2, and it
reverses inflammatory IL-1β effects on chondrocytes, underling the potential of ASU for attenuating
the degenerative effects of IL-1β on cartilage [88].
The combination treatment of ASU with α-lipoic acid (LA) significantly suppressed LPS-, IL-1β-,
or hydrogen peroxide (H2O2)-induced degenerative signaling pathways in equine chondrocytes
in vitro, exerting significant anti-inflammatory and chondroprotective effects compared to controls [95].
Interestingly, the anti-inflammatory effects of ASU are not limited to chondrocytes, as they also target
monocyte/macrophage-like cells in the synovial membrane [96].
A HPLC and gas chromatography (GC) mass spectrometry study showed that the ASU-mediated
inhibition of IL-1β-induced MMP-3 activity, sulfate release, and PGE2 synthesis and that
the ASU-mediated upregulation of GAG and collagen synthesis were dose-dependent [97].
A computer-assisted histomorphometry analysis of the oral administration of ASU in an in vivo
sheep model of OA showed higher levels of PGs, a greater uncalcified cartilage thickness, and a
significant reduction in subchondral bone sclerosis compared to control groups [98]. Interestingly,
it has been shown that supplementation with ASU reduces the development of early OA cartilage
and subchondral bone lesions in a canine model of OA with anterior cruciate ligament defects, and
this effect appeared to be mediated by the inhibition of inducible nitric oxide synthase and MMP-13,
which are key mediators of the structural changes that occur in OA [99]. Early ASU supplementation
in mice has also been shown to stimulate the production of alkaline phosphatase, increase serum
calcium levels, increase chondrocyte counts, and increase cartilage thickness in the middle part of
the tibial plateau [100]. Furthermore, several studies have investigated TE approaches in which ASU
was combined with biocompatible materials or scaffolds. Indeed, in a study with human adipose
tissue-derived mesenchymal stem cells (hADSC) seeded on fibrin-alginate scaffolds, Hashemibeni
and co-workers (2018) showed that Piascledin alone or in combination with TGF-β1 improves the
proliferation, survival, and differentiation of hADSCs [91]. In contrast, in a study on soy isoflavones
alone that examined the chondrogenic differentiation potential of hADSCs, no significantly higher
increase in the expression of COL2A1 or COL2A1 could be found compared to the TGF-β1-stimulated
control group [88].
Taken together, these results underline that a specific component in ASU alone may not have a
large chondrogenic potential, but the combination of components in ASU can significantly enhance
their anti-inflammatory effect and thus stimulate a suitable microenvironment for adequate progenitor
cell chondrogenesis, thus leading to the repair and regeneration of cartilage lesions.
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Table 4. Avocado/soybean unsaponifiables application in cartilage tissue engineering.
First Author References Experimental Model Study Type Findings
Henrotin [88]
Chondrocytes cultured for 72 h
with/without IL-1β and co-treated
with avocado/soybean
unsaponifiables (ASUs) were
analyzed by HPLC and mass
spectrometry. Anti-inflammatory and
anabolic activity was investigated.
in vitro/human chondrocytes
ASU increased the expression of
COL2A1 and AGC genes, cell
proliferation. ASU partially reversed
IL-1β effects on chondrocytes.




Articular chondrocytes were treated
with various concentrations of ASU,
the expression of transforming
growth factor-β (TGF-β1),2, and their
receptors (TGF-βRI and RII) was
determined by Northern blot
and PCR.
in vitro/bovine chondrocytes
ASU induced stimulation of ECM
synthesis by the ability to enhance
TGF-β expression. ASU increased the
production of plasminogen activator
inhibitor (PAI-1), lead to inhibition of
MMP, and induced matrix repair
mechanisms in chondrocytes.
Frondoza [95]
Evaluation of the effects of
ASU/α-lipoic acid (LA) on production
of PGE2 in equine chondrocyte
stimulated with LPS, IL-1β, or H2O2
for 24 h, and supernatants were
immunoassayed for PGE2.
in vitro/equine chondrocytes
Chondrocyte PGE2 production was
inhibited by ASU/LA more effectively
than either alone, which was
associated with the suppression of
NF-κB translocation. ASU/LA on




Evaluation of ASU on
pro-inflammatory mediators in
chondrocytes and monocyte/
macrophage-like cells. Cells were
stimulated for 1 h with LPS, and
analyzed for TNF-α, IL-1β, COX-2,
inducible nitric oxide synthase
(iNOS), and PGE2 expression.
in vitro/chondrocytes
ASU reduced TNF-α, IL-1β, COX-2,
PGE2, and iNOS expression in
LPS-stimulated chondrocytes, and
anti-inflammatory effects of ASU
were observed. ASU also reduced




ASU samples were analyzed by
HPLC, gas chromatography (GC)
mass spectrometry, to clarify, if the
sterol of ASU were the primary
contributors to biological activity in
chondrocytes. The sterol content was
normalized between diverse samples
prior to testing on chondrocytes.
Anti-inflammatory activity was
assayed by measuring of
IL-1β-induced synthesis of PGE2,
MMPs, release of S-35.
in vitro/chondrocytes
ASU samples exerted a
time-dependent upregulation of the
35-sulphate uptake in chondrocytes.
ASU were effective in the
dose-dependent inhibition of
IL-1β-induced MMP-3 activity, PGE2
synthesis. The upregulation of
glycosaminoglycans (GAGs), collagen
synthesis, and the reduction of IL-1β





cells (hADSCs) were seeded in fibrin
or fibrin-alginate scaffolds in
chondrogenic medium containing
Piascledin, TGF-β1, or both.
in vitro/hADSCs/chondrocytes
Piascledin was able to enhance the
proliferation, survival of hADSCs in
scaffolds. However, the expression of
COL2A1 was higher in the TGF-β1
groups, and the expression of AGC
was higher in TGF-β1 alone or with
Piascledin in scaffolds.
6. Pomegranate
Pomegranate (Punica granatum L. (Punicaceae)) is a fruit and a rich source of two types of
polyphenolic compounds: anthocyanins (such as dolphinidin, cyanidin, and pelargonidin), which
give the fruit and juice its red color, and hydrolysable tannins (such as punicalin, pedunculagin,
punicalagin, gallagic, and ellagic acid), which account for 92% of the anti-oxidant activity of the
whole fruit [101,102]. More interestingly, studies have reported that the total anti-oxidant capacity of
pomegranate juice is three times higher than that of popular anti-oxidant-containing beverages such
as red wine and green tea, probably due to the presence of hydrolysable tannins in the peel together
with anthocyanins and ellagic acid derivatives [103,104]. In a comparative analysis, it was found that
anthocyanins from pomegranate have a higher anti-oxidant activity than vitamin E (a-tocopherol),
ascorbic acid, or 3-carotene [103,105]. Pomegranate extract has been shown to protect against NSAIDs
and ethanol-induced gastric ulcers [106], and the whole fruit and its extracts are used in many traditional
medical systems to treat inflammation and pain in OA and other diseases [107]. It has been shown that
the combination of phytochemicals found in the pomegranate fruit has a greater anti-inflammatory
potential compared to a single ingredient application [108].
Previous studies have shown that a standardized pomegranate fruit extract (PFE) inhibits the
production of MMPs by blocking the activation of p38-MAPK and master transcription factor NF-kB in
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OA chondrocytes [109], and they have also shown that the bioavailable metabolites of PFE inhibit the
activity of COX-2 in OA chondrocytes [110]. Furthermore, it has also be shown that the pretreatment
of human OA chondrocytes with PFE inhibits the interleukin IL-1β-induced activation of the upstream
kinase MKK3 and the suppression of reactive oxygen species (ROS) levels, which lead to the inhibition
of the p38 a-MAPK isoform and the activation and DNA-binding activity of the transcription factor
RUNX-2 [111,112]. An in vivo study with rabbits showed that the consumption of PFE significantly
reduced the expression of IL-6, MMPs, and PGE2, while the expression of AGC and COL2A1 was
upregulated [113]. Furthermore, in vivo studies in mice have shown that the ingestion of PFE suppresses
inflammation and joint destruction in a model of collagen-induced arthritis (CIA) [110], prevents
the dose-dependent negative effects of iodoacetate [114], and exerts a significant chondroinductive
potential on mouse embryos in vivo and limb bud cultures in vitro, with increased cell proliferation
and differentiation rates [115]. In patients, the intake of PFE resulted in improved physical function, the
reduced degradation of cartilage enzymes, and the increased anti-oxidant status in patients with knee
OA [116]. Taken together, these data suggest that the consumption of PFE may be chondroprotective,
chondroinductive, and a promising candidate for cartilage TE in the treatment of OA.
Table 5. Pomegranate application in cartilage tissue engineering.
First Author References Experimental Model Study Type Findings
Ahmed [109]
OA chondrocytes or cartilage explants
were pre-treated with pomegranate
fruit extract (PFE), co-treated with
IL-1β. The amounts of PG were
measured with a colorimetric assay.
The expression of MMPs, pIkBα, and
MAPKs was determined by WB and




PFE inhibited the IL-1β-induced PG
breakdown, MMPs expression on
protein and mRNA level, p38-MAPK,
phosphorylation of inhibitor of kappa
B alpha (IkBα), and NF-kB binding to
DNA in OA cartilage explants.
Haseeb [111]
The potential of PFE to suppress
IL-1β-stimulated expression of IL-6,
reactive oxygen species (ROS), and
NF-κB by analyzing the activation of
the kinases upstream of IκBα in PCH
by WB.
in vitro/human chondrocytes
PFE inhibited the mRNA and protein
expression of IL-6, ROS, and
IL-1β-mediated phosphorylation
IKKβ, degradation of IκBα, and
activation and nuclear translocation
of NF-κB/p65 in human chondrocytes.
PFE exerted chondroprotective effects
by suppressing the NF-kB pathway.
Akhtar [113]
OA was surgically induced in the
tibiofemoral joints of rabbits. In one
group, animals were fed PFE in water
for 8 wks postsurgery. In the second
group, animals were fed PFE for 2
wks before surgery and for 8 wks
postsurgery.
in vitro/in vivo rabbit
chondrocytes
PFE-fed rabbits had lower levels of
IL-6, MMP-13, and PGE2 in synovial
fluid/plasma and showed higher
expression of AGC and COL2A1
mRNA. PFE treatment significantly
reduced IL-1β-induced MAPK and
NF-κB inhibitors, and PGE2
production, which highlighted the
chondroprotective effect of PFE in the
treatment of OA.
Monsefi [115]
Pregnant BALB/c mice were given
PFE to investigate the effect on
chondrogenesis. Their embryos were
stained with alizarin red S and alcian
blue. Bone Ca content in pregnant
mice was also measured.
in vitro/in vivo mouse
chondrocytes, MSCs
PFE was able to enhance bone/
cartilage formation. MSCs from fetal
limb buds were cultured, exposed to
PFE, the number of viable cells was
greater than in control cultures. The
number of cartilage nodules and their
diameters were greater in PFE-treated
cultures.
Ghoochani [116]
Patients with knee OA and control
drank 200 mL PFE/daily for 6 weeks,
and the effect of this intervention on
clinical signs was evaluated.
in vivo/OA patients
Significant increases in physical
function of decrease in breakdown of
cartilage enzymes and increase of
anti-oxidant status in patients with
knee OA were observed in PFE group.
7. Resveratrol
The natural stilbenoid resveratrol (3,5,4′-trihydroxy-trans stilbene) is an active food-based
ingredient found in more than 70 common plant species, including the skin of red grapes,
blueberries, raspberries, mulberries, and peanuts. Though it has been used for centuries in
traditional Chinese medicine in various herbal remedies, resveratrol itself was first isolated
from the white hellebore (Veratrum grandiflorum) in 1939 and later from Japanese knotweed in
1963 [90,117,118]. Resveratrol has been shown to have a wide range of protective properties, including
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anti-oxidant, anti-inflammatory, anti-carcinogenic, cardio-protective, and immunomodulating
properties [117,119,120]. The anti-inflammatory [34,121,122], anti-oxidant [123], anti-aging [124]
and anti-OA properties [123,125], which are well-documented in the literature [126], are indeed
remarkable. Furthermore, resveratrol has been reported to modulate the metabolism of lipids and
to suppress the oxidation of low-density lipoproteins and the aggregation of platelets and other
cells. Moreover, like phytoestrogen, resveratrol may provide cardiovascular protection, act in a
chondroinductive fashion [127,128], and have a potential value for regulating bone resorption in
age-related, hormone-dependent, and postmenopausal osteoporosis [129].
It is well-documented that pro-inflammatory cytokines such as IL-1β, TNF-α, and TNF-ß
stimulate matrix-degrading enzymes such as MMPs and COX-2 by promoting NF-κB, which leads
to the destruction of the cartilage matrix and joint inflammation and which plays an important role
in the pathogenesis of RA and OA [37]. Moreover, it has been reported that COX-2 stimulation
induces the synthesis of PGE2, which further mediates inflammation in tissues [130]. The traditional
therapy of OA and RA is carried out by COX inhibitors (NSAIDs). However, NSAIDs have serious
side effects such as stomach ulcers and do not block the synthesis of pro-inflammatory factors and
proteins, which then further promote the breakdown of articular cartilage. This underlines the need for
anti-inflammatory therapy, which on the one hand inhibits COX-2 (and thus prostaglandin synthesis)
but on the other hand may modulate chondrocytes metabolism, further blocking progressive joint
degeneration [131,132]. In fact, Subbaramaiah and co-workers demonstrated that resveratrol is a
potential COX-2 inhibitor and the administration of resveratrol inhibited COX-2 expression and thus
the production of PGE2 [133].
There is a plethora of studies that have explored the potential of resveratrol and OA treatment.
In human chondrocytes, resveratrol has been shown to promote chondrocyte proliferation, the
suppression of IL-1β-induced mitochondrial changes, blocking apoptosis, the upregulation of ROS,
and the production of the tumor suppressor protein p53 [121]. In addition, resveratrol in combination
with curcumin has shown synergistic effects on the suppression of NF-kB pathway activation and the
activation of NF-κB-dependent gene end-products involved in inflammation (COX-2, MMP-9, and
MMP-13), on the suppression of apoptosis by its inhibition of mitochondrial membrane depolarization
and ATP depletion, and on the inhibition of caspase-3 activation [34,122,123,125,134]. Moreover, it was
shown that the TNF-β induction of inflammatory pathways in primary human chondrocytes (PCH)
can be modulated by resveratrol, and that down-regulation of histone deacetylase sirtuin-1 (SIRT1) by
mRNA interference cancelled the effect of resveratrol on TNF-β-induced effects [58]. Furthermore,
ultrastructural and cell viability studies have shown that resveratrol abolishes TNF-β-induced
dose-dependent degrading/apoptotic morphological changes, cell viability, and proliferation in
PCH [58]. Additionally, resveratrol significantly blocks the inflammatory-mediated suppression
of the expression and synthesis of cartilage-specific ECM proteins (COL2A1 and AGC) and the
cartilage-specific transcription factor SOX9 [125,135,136], and it inhibits the SNP-induced expression
of p53 and p21 [135]. Additionally, in vitro investigations have demonstrated that pro-inflammatory
cytokine effects, such as the IL-1β-induced inhibition of chondrocyte proliferation and morphological
changes, are downregulated by resveratrol. Furthermore, resveratrol suppresses membrane-bound
IL-1β and mature IL-1β protein synthesis in cartilage cells. Intriguingly, in IL-1β-stimulated
cells, co-treatment with resveratrol down-regulates caspase-3, PARP cleavage, apoptosis, and
the accumulation of the tumor suppressor gene p53, and it induces the ubiquitin-independent
degradation of p53 [121]. Resveratrol has been further reported to down-regulate the IL-1β-promoted
activation of pro-inflammatory transcription factor NF-kB and NF-κB-regulated pro-inflammatory
and matrix-degrading gene biomarkers, including MMPs, caspase-3, VEGF, and COX-2. Furthermore,
resveratrol suppresses IL-1β-induced IκBα degradation and, consequently, blocks IL-1β-induced IkBα
phosphorylation. Thus, resveratrol suppresses the cytokine-promoted NF-κB-regulated expression
of apoptosis-related gene products by stimulating the accumulation of phosphorylated IκBα, the
ubiquitination of IκBα, and the inhibition of proteasome activity [34,37,122]. In addition, the in vivo
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effects of intra-articular injections of resveratrol on cartilage and synovium were investigated in a
rabbit model of OA, in which resveratrol suppressed the degradation of cartilage tissue and had
a chondroprotective effect on cartilage to prevent experimentally induced OA [137]. Resveratrol
also proved to be a potent intracellular activator of the nuclear histone deacetylase sirtuin-1 (silent
mating-type information regulation; SIRT1), which modulates the inflammatory effects of IL-1β,
TNF-α, and TNF-β and suppresses the expression of HIF-2a [58,138]. Interestingly, it has been
reported that the chondrogenic effects of resveratrol are at least partially mediated by the functional
association between SIRT1 and SOX9, and interruption of this interaction leads to the inhibition of
chondrogenesis [139]. However, the complex mechanism underlying resveratrol in chondrogenesis
remains controversial, since resveratrol not only significantly upregulates SIRT1 gene expression
but also puts chondrocytes into a hypertrophic state in vitro by upregulating COL1, COL10, and
RUNX2 [124]. Furthermore, it was found that the chondroprotective effect of resveratrol is also related
to chondrocyte autophagy by balancing HIF-1α and HIF-2α expressions and thus regulating the
AMPK/mTOR signaling pathway [140]. In fact, it was reported that the administration of resveratrol
in vivo significantly stimulated the activation of SIRT1 and the inhibition of HIF-2α expression in
mouse OA cartilage tissue and in vitro in IL-1β-treated human chondrocytes. These data strongly
indicate that the intra-articular injection of resveratrol significantly prevents the destruction of OA
cartilage tissue through the stimulation of SIRT1, thus reducing the expression of HIF-2α and catabolic
elements [138]. Recently, resveratrol has been found to exert anti-inflammatory activity in chondrocytes
by upregulating miR-146b, thereby deactivating the NF-κB and p38MAPK signaling pathways [141].
The results of all these studies suggest that resveratrol actually acts as a multitargeting agent by
modulating the inflammatory and apoptotic pathway in several steps.
Since resveratrol offers such promising chondroprotective and inductive effects, several studies
have investigated the effect of resveratrol in combination with three-dimensional (3D) environments
on cartilage TE. The intra-articular injection of resveratrol at the beginning of OA protected cartilage
from the development of experimentally induced OA in animal models [142]. Resveratrol promoted
the chondrogenic differentiation of alginate-encapsulated MSCs by modulating β1-integrin signaling
and blocking the IL-1β-mediated activation of NF-kB [117,143]. In 3D-alginate bead cultures and
cartilage graft cultures, resveratrol improved the cell viability of articular chondrocytes, significantly
increased BMP7-promoting PGs synthesis and suppressed the activation of transcription factors
involved in inflammation and catabolic cartilage signaling pathways—including direct downstream
regulators of MAPK and NF-κB and the deactivation of p53-induced apoptosis [134]. Loading a
hyaluronic acid/hydrogel scaffold with resveratrol showed that the oxi-HA/resveratrol hydrogel is
biocompatible with chondrocytes, enables ECM synthesis, and also reduces LPS-induced inflammation
and damage [144]. In addition, Wang et al. (2014) incorporated a macromolecular drug consisting
of resveratrol and polyacrylic acid into collagen to create anti-inflammatory cell-free scaffolds. The
collagen/resveratrol scaffold had the ability to protect the chondrocytes from reactive oxygen species,
osteochondral defects were completely repaired by the collagen/resveratrol scaffold, and the neocartilage
integrated well with the surrounding tissue and subchondral bone [78]. Interestingly, a subsequent
study showed that a continued release of resveratrol from the scaffold into the cell culture medium
blocked IL-1β’s adverse effects (MMP-13 activation) and led to an upregulation of COL2A1, AGC, and
SOX9 mRNA expression [145]. Taken together, results from many three-dimensional studies in vitro
or in vivo underline the promising role of resveratrol for chondroprotective, chondroinductive, and
cartilage TE in future applications. This active ingredient has stimulated innovative scientific concepts
and raised public understanding of preventive health care.
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Table 6. Resveratrol application in cartilage tissue engineering.
First Author References Experimental Model Study Type Findings
Csaki,
Shakibaei [34,146]
Investigation of the potential synergistic effects
of resveratrol or/and curcumin on




Both compounds targeted the NF-κB and MAPK
pathways. Resveratrol inhibits the proteasome,
while curcumin modulates inhibiting upstream
kinases and MAPK.
Buhrmann [58]
PCH were cultured in 3D-alginate cultures,
resveratrol was prepared in ethanol, diluted in
medium. Alginate cultures of PCH were treated




Suppression of TNF-β-, similar to TNF-α- or
T-lymphocytes-induced inflammatory
microenvironment in PCH by resveratrol/histone
deacetylase sirtuin-1 (SIRT1), might be a novel
therapeutic approach for targeting inflammation
during OA/RA.
Wang [78]
Resveratrol grafted to polyacrylic acid to
fabricate collagen/resveratrol scaffolds and
chondrocytes seeded on the scaffolds.
in vitro/in vivo
chondrocytes
Osteochondral defects were completely repaired
by the collagen/resveratrol scaffold, and the




Human PCH in monolayer cultures treated with
IL-1β and co-treated with various concentrations
of resveratrol and evaluated with
((3-(4,5-dimethylthiazol-2-yl)-2,5-




Resveratrol inhibited the expression of VEGF,
MMP-3, MMP-9, and COX-2 in PCH stimulated
with IL-1β. Resveratrol exerted a
chondroprotective capacity by suppression of
IL-1β, ROS, p53-production. and apoptosis by
down-regulation of NF-kB.
Dave [123]
Human chondrocytes and cartilage explants
were isolated from OA patients, treated with
IL-1β and/or resveratrol. Evaluation of PGE2,
leukotriene B




Resveratrol inhibited chondrocyte apoptosis via
inhibition of COX-2-derived PGE2 synthesis by
suppression of mitochondrial membrane
depolarization, depletion. Resveratrol protected
against oxidant injury and apoptosis, which are
main features of progressive OA.
Kim [124]
Healthy and OA chondrocytes were incubated
with various concentrations of resveratrol. Cell
proliferation and gene expressions were
evaluated.
in vitro/chondrocytes
Resveratrol treatment significantly upregulated
SIRT1 gene expression in normal and OA
chondrocytes.
Liu [125]
Chondrocytes were isolated from pig joints;
Resveratrol was prepared as a stock solution
with ethanol. Activation of the IκBα, NF-kB, and
MAPK, activator protein-1 (AP-1) pathways was
assessed by EMSA, WB, and transfection assay.
in vitro/in vivo porcine
chondrocytes
iNOS, COX-2, PGE2 were suppressed by
resveratrol, mediated by inhibiting
IKK-IκBα-NF-κB and JNK/ERK/AP-1pathways
induced by advanced glycation end products
(AGEs). Resveratrol could prevent AGEs-induced
degradation of PG and AGC in cartilage explants.
Im [134] Isolated human PCH, cultured in monolayer or in3D-alginate cultures and treated with resveratrol.
in vitro/human
chondrocytes
Resveratrol improved the viability of PCH,
antagonized protease production, and promoted
PG synthesis as evaluated by (35) S-sulfate
incorporation. Modulation of the downstream
regulators of MAPK and NF-κB. Resveratrol
exerted its chondroprotective actions partly by
inhibition p53-induced apoptosis but not in
chondrosarcoma.
Eo [135]
The effect of resveratrol on NO-induced
apoptosis in rabbit articular chondrocytes was
investigated.
in vitro/chondrocytes
Resveratrol inhibited NO-induced apoptosis
through the NF-κB signaling pathway in articular
chondrocytes.
Maepa [136] Porcine articular chondrocytes were isolatedcultured as monolayers, treated with resveratrol.
in vitro/porcine
chondrocytes
Resveratrol stimulated the expression of collagen
II, regulated collagen II protein in different zones
of articular cartilage.
Elmali [137]
OA model, a unilateral anterior cruciate ligament
transection (ACLT) was performed in rabbits.
Five weeks after the test group had been injected
daily with 10 µM/kg resveratrol in DMSO into
the knees for two weeks, the control group was
injected DMSO into the knees.
in vivo/rabbit
chondrocytes
Intraarticular injections of resveratrol starting at
the onset of OA disease may protect cartilage
against the development of experimentally
induced OA.
Li [138]
Intra-articular injection of resveratrol into a
mouse model of OA. OA was induced in the
mouse knee using the destabilization of the
medial meniscus (DMM). Resveratrol was
injected weekly into the operated knee starting 4
weeks after surgery. The OA phenotype was
investigated by histological and IHC analyses.
in vitro/in vivo human
chondrocytes
Injection of resveratrol significantly prevented the
destruction of OA cartilage by stimulating SIRT1,
thereby suppressing the expression of HIF-2α and
catabolic factors. Activation of SIRT1, the
inhibition of HIF-2α in cartilage tissue and in vitro
in IL-1β-treated chondrocytes.
Jin [141]
Mouse chondrogenic cells were treated with 30
µM resveratrol for 24 h and 10 µg/mL LPS for 12
h. Cell viability, apoptosis and the release of
pro-inflammatory cytokines was assessed.
in vitro/mouse
chondrocytes
Resveratrol supported chondrogenic cell line of
LPS-induced inflammatory apoptotic effects by
upregulation of miR-146b, and deactivation of
NF-κB, p38-MAPK signaling.
Lei [143]
MSC-derived chondrocytes cultured on CGS,
treated with IL-1β and co-treated with
resveratrol and evaluated
ECM, MMPs, and NF-kB.
in vitro/MSCs
chondrocytes
Resveratrol acted as a NF-kB inhibitor to protect
MSC-derived chondrocytes on the CGS from IL-1β
catabolism and these effects were mediated by
β1-integrin.
Sheu [144]
Fabricated and characterized an
Oxi-HA/resveratrol hydrogel for future
applications in cartilage TE.
in vitro/chondrocytes
Oxi-HA/resveratrol hydrogel up-regulated
COL2A1, AGC, and SOX-9 genes, down-regulated
IL-1β and MMPs genes. Oxi-HA/resveratrol
hydrogel is biocompatible with chondrocytes,
allows ECM synthesis, a potentially suitable cell
carrier for chondrocyte in the treatment of cartilage
defects
Wu [145]
Resveratrol-loaded microspheres were fabricated
using oil-in-water emulsion and
solution-evaporation methods. Human bone
marrow MSCs were treated with IL-1β and
co-treated with resveratrol.
in vitro/hMSCs
Resveratrol inhibited the activity of IL-1β, thereby
downregulating MMP-13 mRNA expression.
Up-regulation of COL2A1, AGC, and Sox9 mRNA
expression. Resveratrol maintained chondrogenic
gene expression of cells when exposed to the
inflammatory agents.
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8. Concluding Remarks
The goal of this review was to evaluate the impact of plant-derived phytochemicals (herbal
remedies) on cartilage TE and to highlight the chondrogenesis and chondroinductive effects of these
compounds in studies on resident chondrocytes and progenitor cartilage cells (Figure 2). Articular
cartilage defects are an increasingly frequent phenomenon in the aging community and cause severe
pain, impaired joint function, and significant disability in OA patients. Plant-derived phytochemicals
as potent anti-inflammatory and anti-oxidant agents are a very exciting and profound field of research,
promising for their potential prophylactic properties and for the development of new therapeutic
strategies for the treatment of pro-inflammatory diseases including OA.
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A large body of evidence has shown that a plethora of plants have solid pharmacological properties,
including anti-inflammatory, anti-catabolic, and anti-apoptotic effects, and that they are capable to
protect cartilage from the inflammatory and catabolic effects of various pro-inflammatory cytokines
such as IL-1β, TNF-α, or TNF-β and destructive enzymes such as MMPs and inflammation mediators,
COX-2, released by stimulated and inflamed synoviocytes and by inflammation-induced activated
articular cartilage cells in the joints. Importantly, several studies have reported that the mentioned
cytokines, pro-inflammatory, and degradation mediators are specifically regulated by the central
master pro-inflammatory transcription factor NF-κB. Even more interesting is that the phytochemicals
can effectively suppress the cytokine-induced degradation of the ECM in cartilage tissue by inhibiting
the transcription factor NF-κB signaling pathway.
As discussed, and shown in this review, especially due to their anti-inflammatory and bactericidal
properties, herbal remedies have vast potential in cartilage TE. Furthermore, an important aspect of
successful cartilage TE is the maintenance of adequate scaffold microarchitecture and icroenvironment
so that chondrocytes or progenitor cells can maintain adequate chondrogenic morphology and
promote chondrogenic matrix synthesis. This review highlights that herbal remedies are highly
bio-compatible with various scaffold materials, and with constant drug release, they provide a
favorable microenvironment supporting adequate cartilage repair mechanisms.
To study the role of nutrients in cartilage as anabolic components in cartilage TE, prevention, and
treatment in patients with OA, requires new strategies and large-scale clinical studies that are expected
to take several decades. The clinical studies require a fundamental rethinking of the concept of clinical
examinations in OA. The data should be clinically sound, and the number of exam patients across the
population should be representative and the results should be reproducible.
It is also i portant that the tolerance levels (gastric tolerance, hepatotoxicity, kidney toxicity,
and allergenicity) of the substances in patients is authorized by the European Food Safety Authority
(EFSA) or the US Food and Drug Ad inistration (FDA) [147,148]. Since the echanis s of action of
ost herbal re edies are not yet fully understood and potential discrepancies could arise bet een
the ingredients used in controlled clinical trials and those available to patients, the question of safety
and tolerance as ell as bioavailability does indeed arise. Therefore, for herbal edicinal products to
be included in the routine treat ent of , it is ulti ately of great i portance that phar aceutical
co panies check and standardize the ra aterials used to ensure the safety, efficacy, and quality
of edicinal plant products. ere, the European Scientific Cooperative for Phytotherapy and the
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American Herbal Pharmacopoeia provide comprehensive information on animal experiments, clinical
studies, the quality of medicinal plants, and recommendations for clinical use [149,150]. It is indeed
important and expected that a broad acceptance of phytopharmaceutical interventions and dietary
supplements by physicians is also required for OA patients with well-designed baseline, clinical, and
epidemiological studies. Once these essential hurdles are overcome and answered, nutraceuticals
(herbal remedies) can become a very helpful substitution and supplement to the pain relievers (e.g.,
NSAIDs), which are associated with many side effects and are very used commonly in large quantities
worldwide to treat OA.
Therefore, in the future, plant-derived phytochemicals, as promising non-toxic agents,
anti-inflammatory, and anabolic compounds with chondroinductive potential, can be a beneficial
complementary treatment for OA and regenerative cartilage TE approaches.
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ACI Autologous Chondrocyte Implantation
ACLT Anterior Cruciate Ligament Transection
AGC Aggrecan
AGEs Advanced Glycation End products
AMPK/mTOR Adenosine Monophosphate-activated Protein Kinase/rapamycin
AP-1 Activator Protein-1
ASU Avocado/Soybean Unsaponifiable (ASU)
BALB/c Bagg Albino Laboratory-Bred strain c of the house mouse
BFP-MSCs Buccal Fat Pad-Derived Mesenchymal Stem Cells
BMP-6 Bone Morphogenic Protein-6
CIA Collagen-Induced Arthritis





DJD Degenerative Joint Disease
DMEM Dulbecco’s Modified Eagle’s Medium
DMM Destabilization of the Medial Meniscus
DMSO Dimethyl Sulphoxide
ECM Extracellular Matrix
EFSA European Food Safety Authority
EM Electron Microscopy
EMSA Electrophoretic Mobility Shift Assay






GRE Ginger Root Extract
H2O2 Hydrogen peroxide
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hADSCs Human Adipose Tissue-Derived Mesenchymal Stem Cells
HIF Hypoxia-Inducible Factor
HPG Hyperbranched Polyglycerol
HPLS High Pressure Liquid Chromatography
Ica Icariin
IGF-1 Insulin-Like Growth Factor-1
IHC Immunohistochemistry
Ihh Indian Hedgehog
IkBα Inhibitor of Kappa B Alpha
IKKβ inhibitor of Nuclear Factor Kappa-B Kinase Subunit Beta (IKKβ),
IL-1β Interleukin-1β
IGFBP-3 Insulin-like-growth-factor-binding-protein-3
iNOS Inducible Nitric Oxide Synthase




MAPK Mitogen-Activated Protein Kinase
MKK3 Mitogen-activated protein kinase kinase 3
MMP Matrix Metalloproteinase
MSCs Mesenchymal Stem Cells
MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl-Tetrazolium-Bromid))
NF-κB Nuclear Factor-Kappa B
NO Nitric Oxide
NSAIDs Non-Steroidal Anti-Inflammatory Drugs
OA Osteoarthritis
Oxi-HA/Res Oxidized Hyaluronic Acid/Resveratrol
PAI Plasminogen Activator Inhibitor
PARP Poly(ADP-ribose)-Polymerasen
PCH Primary Human Chondrocytes
PCR Polymerase Chain Reaction.
PFE Pomegranate Fruit Extract
PG Proteoglycan
PGE2 Prostaglandin E2





ROS Reactive Oxygen Species
RUNX-2 Runt-related transcription factor 2
S-35 35-sulfate into proteoglycans
SIRT1 Histone Deacetylase Sirtuin-1
Sirtuin-1 Silent Mating-Type Information Regulation-1
SNP sodium nitroprusside
SOX9 (Sex-Determining Region Y)-Box
TE Tissue Engineering
TGF-β Transforming Growth Factor-β
TGF-βRI Transforming growth factor beta receptor I
TNF-α Tumor-Necrosis Factor
VEGF Vascular Endothelial Growth Factor
WB Western Immunoblotting
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